🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A 🆕️ ⚡️⚡️Cross-sectional survey study Global practice variation of suppressive antimicrobial treatment for prosthetic joint infections #pji #idxposts Substantial global variation in the use of SAT in the management of patients with PJI Nico Cortes-Penfield MD FACP FIDSA 🦴💊 journalofinfection.com/article/S0163-…

I admit I was sceptical. But I’m now convinced that we (#IDTwitter) should all move to Bluesky. Thousands of us have in the past few weeks. Come and join us (and follow me! @gurujosh.bsky.social). I prob won’t be posting here any more

Haven't posted about SNAP for a while: But we've just hit 4000 participants. Almost at 3 years since opening. And submitting two late breaker oral abstracts to ESCMID Global. Amazing progress and more to come. SNAP Trial Joshua Davis Todd C. Lee

Excited to announce that we randomised our first patient into the #ROADMAPtrial today! First of thousands, answering important questions in prosthetic joint infection. See roadmaptrial.com for more deets. #IDXposts #PJI

🆕💫Comparison of surgical treatments for hip and knee periprosthetic joint infections using the desirability of outcome ranking( DOOR) in a prospective multicentre study #IDXposts #PIANO #IEWiki Joshua Davis Todd C. Lee Brad Spellberg jbji.copernicus.org/articles/10/73…

SNAP Trial keeps on chugging. Looking forward to the presentation at ESMID in ~2 weeks. Too bad I am on call and can't attend. Someone record it for me! Steven Tong Joshua Davis

The most anticipated RCT in ID 🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia N:1341 Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia Cefazolin is non-inferior (90d mortality)& less AKI than ASPs A practice-changer RCT that must change the guidelines #ESCMIDGlobal

Oh SNAP Trial. (Flu)cloxacillin was just assassinated. When it comes to MSSA, cefazolin was shown to be non-inferior in terms of mortality and superior in terms of AKI. (Flu)cloxacillin clearly shown to be nephotoxic. Major cudos to Steven Tong, Dr. Joshua Davis, and colleagues.

Agree. My take: - Did we use cefazoline before SNAP? Yes, but not in severe or more complex cases (worried about the inoculum effect issue) - Will we use it now in all cases? Yes. So, practice-changing for us. Well done, Joshua Davis Steven Tong and team

Taking a break from talking about #SNAPtrial to work on a new collaboration #IDSky #ESCMIDglobal Steven Tong

Just thinking that Ortho Bro would be pretty darned excited that cefazolin looked pretty super in the largest S aureus bactermia RCT ever conducted #ESCMIDGlobal "Super ancef" confirmed. No administrative trickery involved. SNAP Trial Joshua Davis Steven Tong Dr. Glaucomflecken

For all those who wondering …are all cl(ox) created equal?? 🕰️

Check out this fun collaboration between #breakpoints and #communicable podcasts about the first SNAP trial results. Steven Tong SIDP podcasts.apple.com/us/podcast/sna…

Selective digestive tract decontamination in ICUs: Life saver or recipe for disaster? By Joshua Davis and Allen Cheng cmi-comms.com/article/S2950-…

In memory of professor Rinaldo Bellomo: A giant of intensive care medi... sciencedirect.com/science/articl…

SNAP Trial is the little engine that could! Congratulations on passing 4500 participants Steven Tong Joshua Davis

Fun to see this in print. This was a hard project because we had to build an EMR interface (had never done before) and then was run during the pandemic! Congratulations Emily McDonald we can reduce potentially inappropriate medications in long term care! jamanetwork.com/journals/jaman…

🧵 “ANA Positive ≠ Lupus: The Art of Interpreting Autoantibodies” ANA positivity is one of the most misunderstood findings in medicine. Here’s how to approach an ANA report systematically, clinically, and with confidence. 👇 #Rheumatology #ANA #Autoimmunity #MedEd Dr. Akhil 🇮🇳

Do you know where the recommendation of adjunctive therapy for E.faecalis IE came from? A case series published in 1954 (with numerous limitations) Time for a well-designed RCT of adjunctive versus monotherapy indeed

Probably the paper I am most proud of. The JAMA IM paper that suggested cefepime was superior is unfortunately flawed in its design. There is no evidence from that study that cefepime is better. Clinicians should treat empirical IV analyses carefully! They are V prone to bias.